BeiGene announced six-year Phase 3 data showing BRUKINSA achieved 74% progression-free survival in treatment-naïve chronic lymphocytic leukemia patients.
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population. For APAC, where CLL is a significant concern, these results reinforce the value of BRUKINSA as a long-term treatment option, potentially improving patient outcomes and quality of life across the region.
BRUKINSA shows 74% 6-year PFS in treatment-naïve CLL.
Data reinforces long-term efficacy and durability.
Significant for CLL treatment options in APAC.
BRUKINSA is a key product for BeiGene in APAC. Demonstrating such strong long-term efficacy in treatment-naïve CLL patients is highly relevant for oncologists and patients in the region, supporting its continued adoption and clinical use.
Data reinforces long-term efficacy and durability.
Significant for CLL treatment options in APAC.
Sign in to save notes on signals.
Sign In